Early and Rapid Detection of Invasive Candidiasis in Human Body Fluids

Many Populations with “Weak” or “Compromised” Immune Systems
are at Risk for Developing Invasive Candidiasis


Patients who have a central venous catheter8,000,000www.who.int/patientsafety/implementation/bsi/en/www.ncbi.nlm.nih.gov/pmc/articles/PMC387407/
Patients in the Intensive Care Unit5,700,000www.sccm.org/Communications/Pages/CriticalCareStats.aspx
Solid organ transplants33,593www.unos.org/data/
Hemopoetic stem cell transplants20,000+www.cibmtr.org/pages/index/aspx
HIV/AIDS patients1,200,000www.cdc.gov/hiv/basics/statistics.html
Patients on dialysis400,000www.niddk.nih.gov/health-information/health-statistics/
Patients with neutropenia60,000www.ncbi.nlm.nih.gov/pmc/articles/PMC3621630/
Cancer patients undergoing chemotherapy650,000www.cdc.gov/cancer/preventinfections/providers.htm

It is estimated that between 46,000 and 90,000 new cases of Invasive Candidiasis occur each year, with a Mortality Rate up to 40%

The Solution: MycoDART-PCR
AdvaTect has patented DNA probes that can be used on most common hospital qPCR platforms. The patented MycoDART-PCRTM allows for the reliable determination of species in 4-6 hours. Candida species include C. albicans, C. krusei, C. parapsilosis,
C. glabrata, C. tropicalis, and C. auris. The patented Aspergillus probes are being developed into a diagnostic panel using the more sensitive MycoDART-PCRTM technology, as are the Mucor probes.